Pharmaceuticals News and Research

RSS

Amorcyte receives patent for chemotactic hematopoietic stem cell product

Amorcyte, Inc., a biopharmaceutical company developing cell therapy products to treat cardiovascular disease, today announced that it has been granted United States Patent number 7,794,705 titled "Compositions and Methods of Vascular Injury Repair." The patent contains both composition of matter and method claims surrounding therapeutic chemotactic hematopoietic stem cell products used in treating or repairing a vascular injury following an acute myocardial infarction (AMI), and delivery of the cell therapy.

13 Sep 2010

Santarus expands development pipeline, adds two novel biologic drug candidates

Santarus, Inc., a specialty biopharmaceutical company, has expanded its development pipeline with the addition of two novel biologic drug candidates focused on specialty markets.

13 Sep 2010

Debiopharm, Aurigene commence IND enabling studies for Debio 0617 inhibitor

Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative prescription drugs that target unmet medical needs, and Aurigene Discovery Technologies Ltd., a Bangalore based fully integrated, global biotech focused on small molecule and peptide drug discovery and development from target identification and validation to pre IND drug candidates, today announced the successful nomination of a development candidate, Debio 0617, a novel inhibitor of an undisclosed oncology pathway.

13 Sep 2010

Genetic misfolding of neuroligins protein may lead to autism spectrum disorders: Research

An international team of scientists, led by researchers at the University of California, San Diego, has identified misfolding and other molecular anomalies in a key brain protein associated with autism spectrum disorders.

13 Sep 2010

Anacor Pharmaceuticals files registration statement with U.S. SEC for initial public offering

Anacor Pharmaceuticals, Inc. today announced that it has filed a registration statement with the U.S. Securities and Exchange Commission ("SEC") relating to the proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. All shares of the common stock to be sold in the offering will be offered by Anacor.

13 Sep 2010

Inovio Pharmaceuticals achieves promising results in VGX-3100 Phase I study

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has achieved best-in-class immune responses in its Phase I dose escalation study of VGX-3100, its DNA vaccine to treat pre-cancerous cervical dysplasias and cervical cancers caused by human papillomavirus (HPV) types 16 and 18.

13 Sep 2010

Bioscience companies to present novel technologies at BioFlorida's conference

A group of a dozen bioscience companies chosen through a competitive process will present their novel technologies to investors, business development executives, scientists and product or service providers at BioFlorida's 13th Annual Conference, scheduled for October 24 - 26 at the Marriott Harbor Beach in Ft. Lauderdale.

13 Sep 2010

Rib-X Pharmaceuticals presents preclinical data of radezolid drug at ICAAC Conference

Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, today announced the presentation of positive preclinical data for radezolid at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) conference.

13 Sep 2010

CRT agrees with AstraZeneca for AZD-3965 clinical trial

Cancer Research UK and Cancer Research Technology the charity's development and commercialisation arm have reached an agreement with AstraZeneca to take compound AZD-3965 a first-of-its-kind experimental drug to potentially treat a range of cancers into clinical trial.

13 Sep 2010

Catch by Gene enters agreement with C&S for HPV test kit

Catch by Gene has entered into an agreement to supply its reagent solutions to C&S Company Ltd commencing immediately in the initial amount of $300,000.

13 Sep 2010

Current economic crisis threatens to affect cancer incidence: Report

Although overall mortality from cancer is decreasing in the European Union, its incidence increased by almost 20%, from 2.1 million new cases in 2002 to 2.5 million in 2008, says a special issue of the European Journal of Cancer on cancer prevention, published today.

13 Sep 2010

Covidien supports FDA labeling changes for gadolinium-based contrast agents

Covidien, a leading global provider of healthcare products, today announced it supports the U.S. Food and Drug Administration's (FDA) labeling changes for gadolinium-based contrast agents for patients with acute kidney injury or chronic, severe kidney disease.

13 Sep 2010

Researchers develop KU-32 drug to prevent diabetic peripheral neuropathy

A drug developed at the University of Kansas has the potential to stop a debilitating condition of diabetes that often leads to pain in the extremities and even amputations, KU researchers have found.

13 Sep 2010

K-V successfully completes FDA inspection for resumption of manufacturing and shipment of products

K-V Pharmaceutical Company announced today that it has received notice from the U.S. Food and Drug Administration ("FDA") of the successful completion of an inspection of the Company's facilities and approval to return its first product to market. Under the Company's Consent Decree, successful FDA inspections of the Company's quality systems, processes and facilities are expected to be required before K-V is permitted to resume manufacturing and shipment of particular products.

10 Sep 2010

Harris Teeter to distribute Oragenics' EvoraPlus and EvoraKids oral care probiotics

Florida-based biopharmaceutical company Oragenics, Inc. has announced the continued retail expansion of its oral care probiotics EvoraPlus and EvoraKids™ with an initial order from Harris Teeter. It is anticipated that the products will be available at Harris Teeter stores in September 2010.

10 Sep 2010

Bioniche reduces net loss per share from $0.15 in fiscal 2009 to $0.02 in fiscal 2010

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its 2010 fiscal year ended June 30, 2010.

10 Sep 2010

Aceto Corporation 2010 fourth quarter net sales increase to $105.8 million

Aceto Corporation, a global leader in the sourcing, quality assurance, regulatory support, marketing and distribution of pharmaceuticals, nutraceuticals, specialty chemicals and crop protection products, today announced results of operations for its fiscal 2010 fourth quarter and year ended June 30, 2010.

10 Sep 2010

395 new vaccines being developed for infectious diseases: PhRMA

Critical challenges remain in the centuries-old battles against infectious diseases, particularly as bacteria and viruses mutate and as the threat of bioterrorism grows. Responding to this need, America's biopharmaceutical research companies this year have 395 new medicines and vaccines in the pipeline to fight infectious diseases. All 395 are in later stages of development, meaning in clinical trials or under Food and Drug Administration (FDA) review.

10 Sep 2010

USIBC to embark Life Sciences Executive Mission for India

The U.S.India Business Council will embark on a Life Sciences Executive Mission to coincide with the Biotechnology Industry Organization's First Annual International Partnering Conference in Hyderabad, India from September 21-22. The mission will be led by Amgen's Dr. Romi Singh, Executive Director of Global Regulatory Affairs and Safety.

10 Sep 2010

John Theurer Cancer Center plays major role in FDA's fast tracking of ipilimumab for metastatic melanoma

Researchers from the John Theurer Cancer Center at Hackensack University Medical Center played an important role in a study that led to the Food & Drug Administration's (FDA) recent fast tracking of ipilimumab, a promising treatment for metastatic melanoma. The FDA based its decision largely on the results of a pivotal study published in the New England Journal of Medicine on August 19, 2010 – the same day the agency accepted Bristol-Myers Squibb's application for the drug's approval and granted the application priority review status.

10 Sep 2010

Pharmaceuticals News and Research

Amorcyte receives patent for chemotactic hematopoietic stem cell product

Santarus expands development pipeline, adds two novel biologic drug candidates

Debiopharm, Aurigene commence IND enabling studies for Debio 0617 inhibitor

Genetic misfolding of neuroligins protein may lead to autism spectrum disorders: Research

Anacor Pharmaceuticals files registration statement with U.S. SEC for initial public offering

Inovio Pharmaceuticals achieves promising results in VGX-3100 Phase I study

Bioscience companies to present novel technologies at BioFlorida's conference

Rib-X Pharmaceuticals presents preclinical data of radezolid drug at ICAAC Conference

CRT agrees with AstraZeneca for AZD-3965 clinical trial

Catch by Gene enters agreement with C&S for HPV test kit

Current economic crisis threatens to affect cancer incidence: Report

Covidien supports FDA labeling changes for gadolinium-based contrast agents

Researchers develop KU-32 drug to prevent diabetic peripheral neuropathy

K-V successfully completes FDA inspection for resumption of manufacturing and shipment of products

Harris Teeter to distribute Oragenics' EvoraPlus and EvoraKids oral care probiotics

Bioniche reduces net loss per share from $0.15 in fiscal 2009 to $0.02 in fiscal 2010

Aceto Corporation 2010 fourth quarter net sales increase to $105.8 million

395 new vaccines being developed for infectious diseases: PhRMA

USIBC to embark Life Sciences Executive Mission for India

John Theurer Cancer Center plays major role in FDA's fast tracking of ipilimumab for metastatic melanoma

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence